I refer to your letter dated 3 February 2020 regarding the Appendix 4C quarterly report for the period ending 31 December 2019 for Elixinol Global Limited (“Elixinol” or “Company”). In response Elixinol advises the following:
Does Elixinol expect that it will continue to have negative operating cashflows for the time being and if not, why not?
For more information, download the attached PDF.
Download this document